Table 5.
Response rates of atomoxetine and placebo in short-term and longer-term studies (integrated analyses).
| Response parameters | Short-term studies integrated analysis |
Longer-term studies integrated analysis |
||||
|---|---|---|---|---|---|---|
| Placebo | ATX | p-value | Placebo | ATX | p-value | |
| CAARS improved by N | 851 | 841 | 557 | 663 | ||
| ≥30%, n (%) | 299 (35.1) | 444 (52.8) | <0.001 | 224 (40.2) | 373 (56.3) | <0.001 |
| ≥40%, n (%) | 215 (25.3) | 347 (41.3) | <0.001 | 175 (31.4) | 292 (44.0) | <0.001 |
| ≥50%, n (%) | 136 (16.0) | 259 (30.8) | <0.001 | 140 (25.1) | 237 (35.8) | <0.001 |
| CAARS improved ≥30% and CGI-ADHD-S ≤3 | 651 | 640 | 557 | 663 | ||
| n (%) | 145 (22.3) | 223 (34.8) | <0.001 | 156 (28.0) | 288(43.4) | <0.001 |
| AAQoL improved by ≥1 SD, N: | 555 | 537 | 344 | 440 | ||
| n (%) | 174 (31.4) | 213 (39.7) | 0.002 | 100 (29.1) | 168 (38.2) | 0.007 |
AAQoL: Adult ADHD Quality-of-Life; ADHD: attention deficit hyperactivity disorder; ATX: atomoxetine; CAARS-Inv: SV: Conners’ Adult ADHD Rating Scale–Investigator-Rated; CGI-ADHD-S: Clinical Global Impressions of ADHD-Severity; N: number of randomized patients per parameter; n: number of patients per sub-parameter; SD: standard deviation.